Alkermes Commences Phase III Study For Schizophrenia Drug
Zacks Investment Research | Jun 11, 2017 10:47PM ET
Alkermes plc (NASDAQ:ALKS) announced that it initiated a phase III study, ENLIGHTEN-Early on experimental candidate, ALKS 3831. The study is a supportive study in the broad clinical development program, ENLIGTHEN on ALKS 3831.
We note that ALKS 3831 is a once-daily, oral atypical antipsychotic drug candidate designed to be a broad-spectrum treatment for schizophrenia.
Alkermes’ share price increased 10.9% year to date as against the Zacks classified Medical - Biomedical and Genetics industry’s gain of 2.2%.
Notably, the ENLIGHTEN clinical development program for ALKS 3831 includes two main studies: a study assessing the antipsychotic efficacy of ALKS 3831 compared with placebo over four weeks and a study evaluating weight gain with ALKS 3831 compared with Eli Lilly and Company’s (NYSE:LLY) Zyprexa (olanzapine) in patients with schizophrenia over a period of six months.
ENLIGHTEN-Early is a 12-week phase III study comparing the weight gain profile of ALKS 3831 to Zyprexa in about 250 young adults with schizophrenia, schizophreniform disorder or bipolar I disorder who are early in their illness. All participants in double-blind portion of study will be eligible to continue in open-label safety study of ALKS 3831 for additional 24 months. In fact, the main purpose of the study is to assess the long-term safety, tolerability and durability of effect of once-daily, oral ALKS 3831.
Moving ahead, the company expects data readouts from the exploratory metabolic study and the pivotal antipsychotic efficacy study by mid-2017.
Schizophrenia is a critical disease and ALKS 3831 has the potential to treat the disease particularly in this young adult population.
Zacks Rank and Stocks to Consider
Alkermes carries a Zacks Rank #4 (Sell). Better-ranked stocks in health care sector include VIVUS, Inc. (NASDAQ:VVUS) and MEI Pharma, Inc. (NASDAQ:MEIP) sporting a Zacks Rank #1 (Strong Buy). You can see .
VIVUS’ loss per share estimates narrowed from 502 cents to 39 cents for 2017 over the last 60 days. The company posted positive earnings surprises in all four trailing quarters, with an average beat of 233.69%. The share price of the company increased 4.4% year to date.
MEI Pharma’s estimates moved up from loss per share of 1 cent to gain per share of the same for 2017, over the last 60 days. The company posted positive earnings surprises in three of the four trailing quarters, with average beat of 66.56%. The share price of the company increased 26.4% year to date.
Get The News You Want
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.